MOMENT registry: Patients with advanced non-small-cell lung cancer harboring MET exon 14 skipping treated with systemic therapy.
Michael Thomas, Petros Christopoulos, Wade T Iams...
https://pubmed.ncbi.nlm.nih.gov/39836056/Actively Recruiting
Led by EMD Serono Research & Development Institute, Inc. · Updated on 2026-10-29
700
Participants Needed
80
Research Sites
N/A
Total Duration
Researchers are collecting detailed data over time on people with advanced non-small cell lung cancer NSCLC who have a specific genetic change called METex14 skipping alterations. This observational disease registry aims to understand how treatments and outcomes evolve for these patients, without changing their usual medical care. It is conducted across multiple countries to gather high-quality, standardized information on this particular lung cancer subgroup. Participants in this registry receive systemic therapy as determined by their doctors in routine clinical practice, without any treatments imposed by the study. Data collection starts when participants join the registry and continues through their treatment and follow-up, until death, loss to follow-up, entry into another clinical trial, or the end of the registry period. The registry does not involve administering any study drugs or interventions. Throughout the study, researchers collect information on participant demographics, clinical features including biomarker data, treatment patterns, and safety. They monitor outcomes such as tumor response using standardized criteria, overall survival, and adverse events. Data collection continues up to nearly five years to capture long-term results, providing valuable insights into real-world treatment effectiveness and patient safety over time.
CONDITIONS
Met Non Small Cell Cancer Registry (MOMENT)
U
US Medical Information
C
Communication Center
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here
EMD Serono Research & Development Institute, Inc.
Lead Sponsor
Merck KGaA, Darmstadt, Germany
Collaborating Sponsor
You may qualify if you...
You will not qualify if you...
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
1 visit (in-person or remote)
Duration - Up to approximately 5 years
Participants receive systemic therapy as usual, while the study collects data on treatments, clinical characteristics, and outcomes over time.
Periodic data collection from medical records and follow-up visits
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
1
Have more questions? Get in touch with our team for quick support
Michael Thomas, Petros Christopoulos, Wade T Iams...
https://pubmed.ncbi.nlm.nih.gov/39836056/EMD Serono Research & Development Institute, Inc.
Lead Sponsor
Merck KGaA, Darmstadt, Germany
Collaborating Sponsor